Clinical development failure
Drug candidates may not show sufficient safety or efficacy to advance, which can end a program after significant R&D spend.
- Scope
- Internal pipeline and co-development programs
- Materiality
- high
Xencor Inc
Xencor Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on engineered antibody therapeutics. The company develops XmAb-based drug candidates and antibody engineering technologies for cancer and autoimmune diseases, and it also licenses its platforms and candidates to collaborators.
−133,0 %
−73,2 %
+13,7 %
6.25
6.25
| % | |
|---|---|
| Proprietary drug candidates | 25% Internally discovered XmAb antibody candidates advanced through preclinical and clinical development. |
| Technology licensing | 35% Licenses to use Xencor's XmAb and Xtend platforms in partner programs. |
| Collaboration milestones | 20% Milestone payments earned when partners achieve development or regulatory events. |
| Royalties | 20% Ongoing royalty income from marketed products developed using Xencor technology. |
Xencor's direct customers are pharmaceutical and biotechnology partners that license its antibody engineering...
- Pharmaceutical collaboratorsprimary
License Xencor's antibody engineering platforms and pay upfront, milestone, and royalty consideration.
- Biotechnology development partnersprimary
Co-develop early-stage antibody programs and use Xencor's technology to accelerate discovery and clinical work.
- Commercial licenseessecondary
Take over selected Xencor-originated candidates for later-stage development and potential commercialization.
- Patients in oncology and autoimmune diseasesecondary
The ultimate end market for Xencor's internal pipeline and partner programs, especially in unmet-need settings.
Xencor is headquartered in Pasadena, California and operates as a U.S.-based research and development company...
- •Headquartered in Pasadena, California
- •Core R&D and corporate functions are U.S.-based
- •Clinical and regulatory work can extend into Europe and other regions
- •Partner manufacturing includes third-party sites in Europe
- •Foreign approvals matter for trials and commercialization
Xencor's strategy is to use its XmAb protein engineering platform to create differentiated antibody therapeutics and...
01
Advance clinical-stage XmAb programsshort-term
Clinical data determine which candidates can move toward later-stage development and potential commercialization.
02
Partner selected assets and technologiesmedium-term
Collaborations provide non-dilutive funding and external development capacity while preserving upside.
03
Expand platform value through XmAb engineeringlong-term
A broader technology base can generate more candidates, more partner programs, and more royalty-bearing products.
Xencor depends on successful clinical development, regulatory approval, and partner execution, all of which are...
Regulatory approval risk
Even promising candidates require FDA and foreign approvals before trials or commercialization can proceed.
- Scope
- Global clinical and commercialization plans
- Materiality
- high
Partner concentration and execution risk
Milestones and royalties depend on third-party partners advancing programs and selling products successfully.
- Scope
- Alexion, Incyte, Amgen and other collaborators
- Materiality
- high
Capital requirements and dilution
Clinical-stage biopharma companies often need external financing before product sales are available.
- Scope
- Pipeline funding and operating flexibility
- Materiality
- high
Intellectual property protection
The value of XmAb technologies depends on patent and license protection against imitation or disputes.
- Scope
- Platform technologies and licensed candidates
- Materiality
- high
Collaboration and license revenue recognition
Can materially shift revenue between periods
Royalty accounting
Creates recurring but partner-dependent revenue
Accrued research and development expenses
Affects operating expense timing
Marketable securities valuation
Can add volatility outside core operations
: 29.4.2026